You are here



It is for their product SOM-0525, an inhaler to treat asthma and chronic obstructive pulmonary disease (COPD).


They have just closed a deal to market a tumor marker for early detection of endometrial cancer with pharmaceutical company Reig-Jofré.


This spin-off, one of the runners-up for the BioEmprenedorXXI award, is developing a new therapy to treat sepsis. 25% of patients in ICUs develop this infection.


These resources will be used to take their new product to treat chemotherapy-resistant cancers into the clinical phases.


The deal is subject to approval of AB-Biotics shareholders at its meeting of next 11th April.


The operation, which will allow Sciclone to use technology developed by Intelligent Pharma to better understand how specific molecules work, will help drivethe Catalan biotechnology company’s international expansion.


These measures respond to the current situation of economic recovery and will facilitate growth and help generate jobs in innovative companies.


The new plant has 6,200 square meters of floor space and will manufacture large-scale sterilizers for hospitals and research centers.


Catalan Telstar and British Puretech Process Systems have been strategic partners since the end of last year. Jordi Net, Telstar Sales Marketing Director says, “The new brand is synonymous with high quality and lower life-cycle prices.”


This operation will increase the group’s presence in the United States, where they have already ensured plasma supply with 80 plasmapheresis centers.